ReviewCritical care (London, England)2008
The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy.
Review in Critical care (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 41 citations in OpenAlex.
- Endothelin-1 in combination with CRB-65 enhance risk stratification in COVID-19 patients.Infection · 2025Article
- The incremental value of aspartate aminotransferase/alanine aminotransferase ratio combined with CURB-65 in predicting treatment outcomes in hospitalized adult community-acquired pneumonia patients with type 2 diabetes mellitus.BMC pulmonary medicine · 2025Article
- Discovery and predictive modeling of urine microbiome, metabolite and cytokine biomarkers in hospitalized patients with community acquired pneumonia.Scientific reports · 2020Article
- Clinical, Laboratory and Radiographic Features of Patients with Pneumonia and Parapneumonic Effusions.Open access Macedonian journal of medical sciences · 2016Article
- The value of mean platelet volume in the determination of community acquired pneumonia in children.Italian journal of pediatrics · 2013Article
- Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly.Immunity · 2012Review
- Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study.Critical care (London, England) · 2012Observational
- Is procalcitonin better than C-reactive protein for early diagnosis of bacterial pneumonia in children?Journal of clinical laboratory analysis · 2010Article
- Severe community-acquired pneumonia and PIRO: a new paradigm of management.Current infectious disease reports · 2009Article
- Biomarkers: a definite plus in pneumonia.Mediators of inflammation · 2009Review
- Severe community acquired pneumonia update: mortality, mechanisms and medical intervention.Critical care (London, England) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with community-acquired pneumonia (CAP) in the hospital setting exhibit markedly abnormal levels of various biomarkers of infection, inflammation and coagulation. CAP is a well characterized disease, relatively homogeneous and amenable to management according to defined protocols. Hence, this group of patients represents an opportunity to investigate further these biomarkers as a means of determining disease severity and identifying candidates for new therapies. Changes in biomarker levels during the course of disease may enable physicians to identify those patients who are most at risk for deterioration and progression toward severe CAP and who are in greatest need of early intervention. Subgroup analysis of the placebo-controlled OPTIMIST trial of tifacogin in severe sepsis revealed a trend toward benefit in patients with procalcitonin levels of 2 ng/ml or greater and in those with high baseline markers of activated coagulation. Biomarker studies are being undertaken as part of the ongoing CAPTIVATE study. This study includes patients with severe CAP and will compare the efficacy and safety of recombinant tissue factor pathway inhibitor (tifacogin) versus placebo. In the future it may also be possible to use genomic markers to identify patients at greatest risk for deterioration or complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.